Gender and the prevalence and progression of renal disease

Advances in Chronic Kidney Disease

Volumn 20, Issue 5, 2013, Pages 390-395

  Neugarten, Joel ^a   Golestaneh, Ladan ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CKD; Estrogen; Gender; Sex; Testosterone

Indexed keywords

CAPTOPRIL; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ESTROGEN RECEPTOR ALPHA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SMAD PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

AGE DISTRIBUTION; APOPTOSIS; BLOOD PRESSURE; CALORIC INTAKE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIET; DIETARY INTAKE; DISEASE COURSE; ENVIRONMENTAL FACTOR; GLOMERULUS FILTRATION RATE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY STRUCTURE; LIPID METABOLISM; MACROALBUMINURIA; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION;

CKD; ESTROGEN; GENDER; SEX; TESTOSTERONE;

DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GONADAL STEROID HORMONES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SEX FACTORS;

EID: 84882761422     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.05.004     Document Type: Review

References (44)

1. Silbiger S., Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995, 25(4):515-533.
2. Neugarten J., Acharya A., Silbiger S.R. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000, 11(2):319-329.
3. Coggins C.H., Lewis J.B., Caggiula A.W., Castaldo L.S., Klahr S., Wang S.R. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998, 13(6):1430-1437.
4. Jafar T.H., Schmid C.H., Stark P.C., et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 2003, 18(10):2047-2053.
5. Cattran D.C., Reich H.N., Beanlands H.J., et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008, 23(7):2247-2253. Genes, Gender and Glomerulonephritis Group.
6. Ruggenenti P., Perna A., Zoccalli C., et al. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between men and women in relation to the ACE gene polymorphism. J Am Soc Nephrol 2000, 11(1):88-96. "Gruppo Italiano di Studi Epidemologici in Nefrologia" (GISEN).
7. Evans M., Fryzek J.P., Elinder C.G., et al. The natural history of chronic renal failure: results from an unselected population-based inception cohort in Sweden. Am J Kidney Dis 2005, 46(5):863-870.
8. Eriksen B.O., Ingebretsen O.C. The progression of chronic kidney disease: a 10 year population-based study of the effects of gender and age. Kidney Int 2006, 69(2):375-382.
9. Hallan S.I., Ritz E., Lyndersen S., Romundstad S., Kvenild K., Orth S.R. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009, 20(5):1069-1077.
10. Iseki K., Iseki C., Ikemiya Y., Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996, 49(3):800-805.
11. Haroun M.K., Jarr B.G., Hoffman S.C., Comstock G.W., Klag M.J., Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003, 14(11):2934-2941.
12. Babayev R., Whaley-Connell A., Kshirsagar A., et al. Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013, 61(3):404-412.
13. Nitsch D., Grams M., Sang Y., et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013, 346:f324. Chronic Kidney Disease Prognosis Consortium.
14. U.S. Renal Data System. USRDS 2012 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States 2012, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
15. Gilg J., Castledine C., Fogarty D. UK Renal Registry 14th annual report: Chapter 1 UK RRT incidence in 2010: National and centre-specific analyses. Nephrol Clin Pract 2012, 120(suppl 1):c1-c27.
16. ERA-EDA Registry Annual Report. Available at: . Accessed May 15, 2013. http://www.espn-reg.org.
17. Iseki K., Nakai S., Shinzato T., Nagura Y., Akiba T. Increasing gender difference in the incidence of chronic dialysis therapy in Japan. Ther Apher Dial 2005, 9(5):407-411. Patient Registration Committee of the Japanese Society for Dialysis Therapy.
18. Harjutsalo V., Maric C., Forsblom C., Thorn L., Waden J., Groop P.H. Sex related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia 2011, 54(8):1992-1999. FinnDiane Study Group.
19. Orchard T.J., Dorman J.S., Maser R.E., et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990, 39(9):1116-1124.
20. Raile K., Galler A., Hoffer S., et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes. Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007, 30(10):2523-2528.
21. Breyer J.A., Bain R.P., Evans J.K., et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 1996, 50(5):1651-1658.
22. Maric C., Sullivan S. Estrogens and the diabetic kidney. Gend Med 2008, 5(suppl A):S103-S113.
23. Ravid M., Brosh D., Ravid-Safran D., Levy Z., Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med 1998, 158(9):998-1004.
24. Keane W.F., Brenner B.M., de Zueeuw D., et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int 2003, 63(4):1499-1507. RENAAL Study investigators.
25. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860. Collaborative Group.
26. Centers for Disease Control and Prevention. Age-adjusted incidence of end-stage renal disease related to diabetes mellitus (ESRD-DM) per 100,000 diabetic population, by race, ethnicity, and sex, United States, 1980-2008. Available at: . Accessed May 15, 2013. http://www.cdc.gov/diabetes/statistics/esrd/fig5.htm.
27. Icks A., Haastert B., Genz J., et al. Incidence of renal replacement therapy (RRT) in the diabetic population in a German region, 2002-2008. Nephrol Dial Transplant 2011, 26(1):264-269.
28. Zdunek M., Silbiger S., Lei J., Neugarten J. Protein kinase CK2 mediates TGF-β1-stimulated type IV collagen gene transcription and its reversal by estradiol. Kidney Int 2001, 60(6):2097-2108.
29. Negulescu O., Bognar I., Lei J., Devarajan P., Silbiger S., Neugarten J. Estradiol reverses TGF-β1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney Int 2002, 62(6):1989-1998.
30. Ito I., Hanyu A., Wayama M., et al. Estrogen inhibits transforming growth factor eta signaling by promoting Smad 2/3 degradation. J Biol Chem 2010, 285(19):14747-14755.
31. Dixon A., Maric C. 17β-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling. Am J Physiol 2007, 293(5):F1678-F1690.
32. Neugarten J., Medve I., Lei J., Siliger S.R. Estradiol suppresses mesangial cell type I collagen synthesis via activation of the MAP kinase cascade. Am J Physiol 1999, 277(6 Pt 2):F875-F881.
33. Guccione M., Silbiger S., Lei J., Neugarten J. Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. Am J Physiol 2002, 282(1):F164-F169.
34. Blush J., Lei J., Ju W., Silbiger S., Pullman J., Neugarten J. Estradiol reverses renal injury in Alb/TGF-β1 transgenic mice. Kidney Int 2004, 66(6):2148-2154.
35. Neugarten J., Silbiger S.R., Golestaneh L. Gender and kidney disease. Brenner and Rector's The Kidney 2008, 674-680. Elsevier, Amsterdam, The Netherlands. 9th ed. B.M. Brenner (Ed.).
36. Kang A.K., Miller J.A. Effects of gender on the renin-angiotensin system, blood pressure, and renal function. Curr Hypertens Rep 2002, 4(2):143-151.
37. Miller J.A., Abacta L.A., Cattran D.C. Impact of gender on renal response to angiotensin II. Kidney Int 1999, 55(1):278-285.
38. Tostes R.C., Rortes Z.B., Callera G.E., et al. Endothelin, sex and hypertension. Clin Sci (Lond) 2008, 114(2):85-97.
39. Cherney D.Z.I., Sochett E.B., Miller J.A. Gender differences in renal response to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int 2005, 68(4):1722-1728.
40. Cherney D.Z.I., Scholey J.W., Nasrallah R., et al. Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type1 diabetes mellitus. Am J Physiol 2008, 294(6):F1336-F1341.
41. Neugarten J. Estrogen and oxidative stress. Gend Med 2007, 4(1):31-32.
42. Doublier S., Lupia E., Catanuto P., et al. Testosterone and 17 beta-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int 2011, 79(4):404-413.
43. Verzola D., Villagio B., Procopio V., et al. Androgen-mediated apoptosis of kidney tubule cells: role of c-Jun amino terminal kinase. Biochem Biophys Res Commun 2009, 387(3):531-536.
44. Melamed M.L., Blackwell T., Neugarten J., et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int 2011, 79(2):241-249.